Drug
Moxidectin clinical trials
- studies test it
- 23
- open now
- 1
- in phase 3
- 9
- first study started
- 2006
Keep track of what changes. Save the moxidectin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 9
- Phase 3
- 9
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 18
Medicines Development for Global Health (8) · Jennifer Keiser (5) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Washington University School of Medicine (2) · Eye Research Foundation, Inc. (1) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1) · Swiss Tropical & Public Health Institute (1) · Kirby Institute (1)
Often tested with
Tested in the same studies.
Ivermectin (6) · Albendazole (4) · Diethylcarbamazine (2) · Midazolam (1)
Studies
Open first, then newest update. How each study uses moxidectin is read from its arms, and is right about nine times in ten.
Testing it · 23
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesRecruitingPhase 4Kirby InstituteNCT07145736Written as Moxidectin
- Efficacy and Safety Study of Moxidectin in Adults With ScabiesCompletedPhase 2Medicines Development for Global HealthNCT05875441Written as Moxidectin Oral Product
- Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant AlbendazoleCompletedPhase 3Medicines Development for Global HealthNCT04311671Written as Moxidectin
- Moxidectin for LF, Cote d'Ivoire (DOLF)CompletedPhase 3Washington University School of MedicineNCT04410406Written as Moxidectin
- Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisActive, not recruitingPhase 3Medicines Development for Global HealthNCT03876262Written as Moxidectin
- Safety and Efficacy of Novel Combination Regimens for Treatment of OnchocerciasisActive, not recruitingPhase 2Washington University School of MedicineNCT06070116Written as Moxidectin + Albendazole
- Efficacy and Safety of Moxidectin-Albendazole Co-administration in SACCompletedPhase 3Jennifer KeiserNCT06188715Written as Moxidectin 2 mg Oral Tablet
- A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 YearsCompletedPhase 1Medicines Development for Global HealthNCT03962062Written as Moxidectin
- Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash InfestationCompletedPhase 4Eye Research Foundation, Inc.NCT06795165Written as Moxidectin 2 MG Oral Tablet
- Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 Mg Ivermectin-controlled in Loa Loa Microfilaremic PatientsCompletedPhase 2Center for Research on Filariasis and Other Tropical Diseases, CameroonNCT04049851Written as Moxidectin 2 MG Oral Tablet
- Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides StercoralisCompletedPhase 2/3Jennifer KeiserNCT04056325Written as Moxidectin
- Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administrationCompletedPhase 2/3Jennifer KeiserNCT04700423Written as moxidectin (8 mg) / albendazole (400 mg)
- Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides StercoralisCompletedPhase 3Jennifer KeiserNCT04848688Written as Moxidectin 2 mg
- Efficacy and Safety of MOX/ALB Co-administrationCompletedPhase 3Jennifer KeiserNCT04726969Written as Moxidectin 2 mg Oral Tablet
- Dose-finding Study of Moxidectin for Treatment of ScabiesCompletedPhase 2Medicines Development for Global HealthNCT03905265Written as Moxidectin Oral Product
- Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus InfectionCompletedPhase 2Medicines Development for Global HealthNCT00300768Written as 2 mg moxidectin
- Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy VolunteersCompletedPhase 1Medicines Development for Global HealthNCT03012828Written as Moxidectin
- Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris TrichiuraCompletedPhase 2Swiss Tropical & Public Health InstituteNCT03501251Written as Moxidectin 8mg
- Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus InfectionCompletedPhase 3Medicines Development for Global HealthNCT00790998Written as Moxidectin
- Pediatric Pharmacokinetics And Safety Study Of MoxidectinWithdrawnPhase 2PfizerNCT01035619Written as moxidectin
Codes
What other systems call moxidectin · ClinicalTrials.gg INT002863
- MeSH (NLM) C027837moxidectinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) NGU5H31YO9MOXIDECTINConfirmed FDA, NLM, Wikidata
- RxNorm 1047072Confirmed FDA, Wikidata
- Wikidata Q903824moxidectinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73264MoxidectinConfirmed FDA, Wikidata
- DrugBank DB11431One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C027837 | moxidectin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | NGU5H31YO9 | MOXIDECTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1047072 | — | Confirmed FDA, Wikidata |
| Wikidata | Q903824 | moxidectin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73264 | Moxidectin | Confirmed FDA, Wikidata |
| DrugBank | DB11431 | — | One source Wikidata |
Also registered as milbemectin (UNII 207B6WP2MZ), milbemycin a3 (UNII C76Y8Z9GEX), milbemycin a4 (UNII 9BSH89E55Y) and milbemycin d (UNII 04S0E2XJQI).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.